Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors

Vincent Chau, S. Kyun Lim, Wei Mo, Chiachi Liu, Amish J. Patel, Renée M. McKay, Shuguang Wei, Bruce A. Posner, Jef K. De Brabander, Noelle S. Williams, Luis F. Parada, Lu Q. Le

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Neurofibromatosis type I (NF1) is an autosomal disorder that affects neural crest-derived tissues, leading to a wide spectrum of clinical presentations. Patients commonly present with plexiform neurofibromas, benign but debilitating growths that can transform into malignant peripheral nerve sheath tumors (MPNST), a main cause of mortality. Currently, surgery is the primary course of treatment for MPNST, but with the limitation that these tumors are highly invasive. Radiotherapy is another treatment option, but is undesirable because it can induce additional mutations. Patients with MPNST may also receive doxorubicin as therapy, but this DNA-intercalating agent has relatively low tumor specificity and limited efficacy. In this study, we exploited a robust genetically engineered mouse model of MPNST that recapitulates human NF1-associated MPNST to identify a novel small chemical compound that inhibits tumor cell growth. Compound 21 (Cpd21) inhibits growth of all available in vitro models of MPNST and human MPNST cell lines, while remaining nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts. We show that this compound delays the cell cycle and leads to cellular apoptosis. Moreover, Cpd21 can reduce MPNST burden in a mouse allograft model, underscoring the compound's potential as a novel chemotherapeutic agent.

Original languageEnglish (US)
Pages (from-to)586-597
Number of pages12
JournalCancer Research
Volume74
Issue number2
DOIs
StatePublished - Jan 15 2014

Fingerprint

Neurilemmoma
Apoptosis
Therapeutics
Growth
Plexiform Neurofibroma
Intercalating Agents
Neoplasms
Neurofibromatosis 1
Neural Crest
Schwann Cells
Tumor Burden
Tumor Cell Line
Genetic Therapy
Doxorubicin
Allografts
Cell Cycle
Radiotherapy
Fibroblasts
Mutation
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. / Chau, Vincent; Lim, S. Kyun; Mo, Wei; Liu, Chiachi; Patel, Amish J.; McKay, Renée M.; Wei, Shuguang; Posner, Bruce A.; De Brabander, Jef K.; Williams, Noelle S.; Parada, Luis F.; Le, Lu Q.

In: Cancer Research, Vol. 74, No. 2, 15.01.2014, p. 586-597.

Research output: Contribution to journalArticle

@article{13d1865b28ee4857a4e1654b44a0b3ff,
title = "Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors",
abstract = "Neurofibromatosis type I (NF1) is an autosomal disorder that affects neural crest-derived tissues, leading to a wide spectrum of clinical presentations. Patients commonly present with plexiform neurofibromas, benign but debilitating growths that can transform into malignant peripheral nerve sheath tumors (MPNST), a main cause of mortality. Currently, surgery is the primary course of treatment for MPNST, but with the limitation that these tumors are highly invasive. Radiotherapy is another treatment option, but is undesirable because it can induce additional mutations. Patients with MPNST may also receive doxorubicin as therapy, but this DNA-intercalating agent has relatively low tumor specificity and limited efficacy. In this study, we exploited a robust genetically engineered mouse model of MPNST that recapitulates human NF1-associated MPNST to identify a novel small chemical compound that inhibits tumor cell growth. Compound 21 (Cpd21) inhibits growth of all available in vitro models of MPNST and human MPNST cell lines, while remaining nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts. We show that this compound delays the cell cycle and leads to cellular apoptosis. Moreover, Cpd21 can reduce MPNST burden in a mouse allograft model, underscoring the compound's potential as a novel chemotherapeutic agent.",
author = "Vincent Chau and Lim, {S. Kyun} and Wei Mo and Chiachi Liu and Patel, {Amish J.} and McKay, {Ren{\'e}e M.} and Shuguang Wei and Posner, {Bruce A.} and {De Brabander}, {Jef K.} and Williams, {Noelle S.} and Parada, {Luis F.} and Le, {Lu Q.}",
year = "2014",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-13-1934",
language = "English (US)",
volume = "74",
pages = "586--597",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors

AU - Chau, Vincent

AU - Lim, S. Kyun

AU - Mo, Wei

AU - Liu, Chiachi

AU - Patel, Amish J.

AU - McKay, Renée M.

AU - Wei, Shuguang

AU - Posner, Bruce A.

AU - De Brabander, Jef K.

AU - Williams, Noelle S.

AU - Parada, Luis F.

AU - Le, Lu Q.

PY - 2014/1/15

Y1 - 2014/1/15

N2 - Neurofibromatosis type I (NF1) is an autosomal disorder that affects neural crest-derived tissues, leading to a wide spectrum of clinical presentations. Patients commonly present with plexiform neurofibromas, benign but debilitating growths that can transform into malignant peripheral nerve sheath tumors (MPNST), a main cause of mortality. Currently, surgery is the primary course of treatment for MPNST, but with the limitation that these tumors are highly invasive. Radiotherapy is another treatment option, but is undesirable because it can induce additional mutations. Patients with MPNST may also receive doxorubicin as therapy, but this DNA-intercalating agent has relatively low tumor specificity and limited efficacy. In this study, we exploited a robust genetically engineered mouse model of MPNST that recapitulates human NF1-associated MPNST to identify a novel small chemical compound that inhibits tumor cell growth. Compound 21 (Cpd21) inhibits growth of all available in vitro models of MPNST and human MPNST cell lines, while remaining nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts. We show that this compound delays the cell cycle and leads to cellular apoptosis. Moreover, Cpd21 can reduce MPNST burden in a mouse allograft model, underscoring the compound's potential as a novel chemotherapeutic agent.

AB - Neurofibromatosis type I (NF1) is an autosomal disorder that affects neural crest-derived tissues, leading to a wide spectrum of clinical presentations. Patients commonly present with plexiform neurofibromas, benign but debilitating growths that can transform into malignant peripheral nerve sheath tumors (MPNST), a main cause of mortality. Currently, surgery is the primary course of treatment for MPNST, but with the limitation that these tumors are highly invasive. Radiotherapy is another treatment option, but is undesirable because it can induce additional mutations. Patients with MPNST may also receive doxorubicin as therapy, but this DNA-intercalating agent has relatively low tumor specificity and limited efficacy. In this study, we exploited a robust genetically engineered mouse model of MPNST that recapitulates human NF1-associated MPNST to identify a novel small chemical compound that inhibits tumor cell growth. Compound 21 (Cpd21) inhibits growth of all available in vitro models of MPNST and human MPNST cell lines, while remaining nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts. We show that this compound delays the cell cycle and leads to cellular apoptosis. Moreover, Cpd21 can reduce MPNST burden in a mouse allograft model, underscoring the compound's potential as a novel chemotherapeutic agent.

UR - http://www.scopus.com/inward/record.url?scp=84892919717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892919717&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-1934

DO - 10.1158/0008-5472.CAN-13-1934

M3 - Article

VL - 74

SP - 586

EP - 597

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 2

ER -